Scpharmaceuticals Stock Alpha and Beta Analysis
| SCPH Stock | USD 3.35 0.11 3.18% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Scpharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Scpharmaceuticals over a specified time horizon. Remember, high Scpharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Scpharmaceuticals' market risk premium analysis include:
Beta 2 | Alpha (0.81) | Risk 3.59 | Sharpe Ratio (0.17) | Expected Return (0.62) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Scpharmaceuticals |
Scpharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Scpharmaceuticals market risk premium is the additional return an investor will receive from holding Scpharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Scpharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Scpharmaceuticals' performance over market.| α | -0.81 | β | 2.00 |
Scpharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Scpharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Scpharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Scpharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Scpharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Scpharmaceuticals shares will generate the highest return on investment. By understating and applying Scpharmaceuticals stock market price indicators, traders can identify Scpharmaceuticals position entry and exit signals to maximize returns.
Scpharmaceuticals Return and Market Media
The median price of Scpharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 4.41 with a coefficient of variation of 12.89. The daily time series for the period is distributed with a sample standard deviation of 0.58, arithmetic mean of 4.52, and mean deviation of 0.48. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by John Tucker of 100000 shares of Scpharmaceuticals subject to Rule 16b-3 | 08/30/2024 |
2 | Acquisition by Rachael Nokes of 85750 shares of Scpharmaceuticals subject to Rule 16b-3 | 09/03/2024 |
3 | Investors in scPharmaceuticals have unfortunately lost 23 percent over the last year | 09/16/2024 |
4 | scPharmaceuticals Inc. Short Interest Update | 09/30/2024 |
5 | BioMarin Pharmaceutical Tops Q3 Earnings and Revenue Estimates | 10/29/2024 |
6 | TScan Therapeutics Soars 7.6 percent Is Further Upside Left in the Stock | 11/07/2024 |
7 | scPharmaceuticals GAAP EPS of -0.75 misses by 0.45, revenue of 10.02M misses by 0.78M | 11/13/2024 |
8 | Acquisition by Schaeffer Leonard D of 6124 shares of Scpharmaceuticals at 3.37 subject to Rule 16b-3 | 11/15/2024 |
9 | scPharmaceuticals Inc. Shares Slammed 26 percent But Getting In Cheap Might Be Difficult Regardless | 11/19/2024 |
About Scpharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Scpharmaceuticals or other stocks. Alpha measures the amount that position in Scpharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.95 | 1.0 | Days Of Inventory On Hand | 846.65 | 804.32 |
Scpharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Scpharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Scpharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Scpharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Scpharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Scpharmaceuticals' management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Scpharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Scpharmaceuticals Backtesting, Scpharmaceuticals Valuation, Scpharmaceuticals Correlation, Scpharmaceuticals Hype Analysis, Scpharmaceuticals Volatility, Scpharmaceuticals History and analyze Scpharmaceuticals Performance. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Scpharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.